Quantitative detection of inhaled salmeterol in human urine and relevance to doping control analysis

Therapeutic Drug Monitoring

Volumn 33, Issue 5, 2011, Pages 627-631

  Deventer, Koen ^a   Pozo, Oscar J ^a,b   Delbeke, Frans T ^a   Van Eenoo, Peter ^a  

^a GHENT UNIVERSITY   (Belgium)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

detection; doping; mass spectrometry; salmeterol; urine

Indexed keywords

2 PROPANOL; ETHER; SALMETEROL XINAFOATE; SEREVENT EVOHALER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DOPING; DRUG URINE LEVEL; ELECTROSPRAY; HUMAN; HYDROLYSIS; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

ADULT; ALBUTEROL; BRONCHODILATOR AGENTS; CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80053573859     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318229c5f4     Document Type: Article

References (20)

1. Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41:19-30. (Pubitemid 34158086)
2. Polettini A. Bioanalysis of beta 2-agonists by hyphenated chromatographic and mass spectrometric techniques. J Chromatogr B Biomed Appl. 1996;687:27-42. (Pubitemid 27008304)
3. The 2010 Prohibited List, International Standard (2010)World Anti-Doping Agency (WADA). Available at: http://www.wada-ama.org/Documents/World-Anti- Doping-Program/WADP-Prohibited-list/WADA-Prohibited-List-2010-EN.pdf. Accessed January 13, 2011.
4. WADA. 2010 Prohibited List, Summary of Major Modifications. Montreal, Canada: World Anti-Doping Agency (WADA); 2010.
5. Van Thuyne W, Delbeke FT. Declared use of medication in sports. Clin J Sport Med. 2008;18:143-147. (Pubitemid 351365720)
6. Ventura R, Damasceno L, Farre M, et al. Analytical methodology for the detection of beta(2)-agonists in urine by gas chromatography-mass spectrometry for application in doping control. Anal Chim Acta. 2000; 418:79-92. (Pubitemid 30421076)
7. De Boer D, Van Beek M, Bekkers CHJ, et al. The detection of the administration of salmeterol in urine after inhalation. In: Schänzer W, Geyer H, Gotzmann A, et al, eds. Recent Advances in Doping Analysis (4), Proceedings of the 14th Cologne Workshop on Dope Analysis. Cologne, Germany: Sport & Buch Strauss; 2004:357-363.
8. Verwaal W, van Bavel M, Boot A, et al. Valideren van (fysisch-) chemische en (fysisch-) mechanische methoden op het niveau van de wettelijke eis. De ware(n)-chemicus. 1996;26:1-16.
9. Bressolle F, BrometPetit M, Audran M. Validation of liquid chromatographic and gas chromatographic methods-applications to pharmacokinetics. J Chromatogr B. 1996;686:3-10. (Pubitemid 26382452)
10. Damasceno L, Ventura R, Ortuno J, et al. Derivatization procedures for the detection of beta(2)-agonists by gas chromatographic/mass spectrometric analysis. J Mass Spectrom. 2000;35:1285-1294.
11. Morgan DJ. Clinical pharmacokinetics of beta-agonists. Clin Pharmacokinet. 1990;18:270-294.
12. Van Eenoo P, Deventer K, Delbeke FT. Quantitative detection of salmeterol after inhalation in equine urine by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2002;16:1755-1759. (Pubitemid 35033733)
13. Thevis M, Opfermann G, Schanzer W. Liquid chromatography/electrospray ionization tandem mass spectrometric screening and confirmation methods for beta(2)-agonists in human or equine urine. J Mass Spectrom. 2003;38:1197-1206. (Pubitemid 37508687)
14. Bres J, Clauzel AM, Pistre MC, et al. Metabolism of beta-adrenoceptor stimulants-therapeutic implications [in French]. Bull Eur Physiopathol Respir. 1985;21:S19-S34.
15. Henze MK, Opfermann G, Spahn-Langguth H, et al. Screening of beta-2 agonists and confirmation of fenoterol, orciprenaline, reproterol and terbutaline with gas chromatography-mass spectrometry as tetrahydroisoquinoline derivatives. J Chromatogr B Biomed Sci Appl. 2001;751: 93-105. (Pubitemid 32146318)
16. Henze MK, Opfermann G, Schänzer W. Liquid-liquid extraction pHprofiles of selected beta-2-sympathomimetic agonists. In: Schänzer W, Geyer H, Gotzmann A, et al, eds. Recent Advances in Doping Analysis (7), Proceedings of the 17th Cologne Workshop on Dope Analysis. Cologne, Germany: Sport & Buch Strauss; 1999:335-339.
17. Wilkinso GR, Beckett AH. Absorption metabolism and excretion of ephedrines in man .I. Influence of urinary pH and urine volume output. J Pharmacol Exp Ther. 1968;162:139-147.
18. Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl. 1982;63:86-95. (Pubitemid 13235843)
19. Hochhaus G, Mollmann H. Pharmacokinetic pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992;30:342-362.
20. Patient Information Leaflet Serevent Evohaler (March 2007) GlaxoSmithKline (GSK). Available at: http://www.medicines.org.uk/emc/document. aspx?documentid=17202&docType=PIL. Accessed August 8, 2011.